Kidney Legislation Before Congress
Below is a list of kidney-related legislation that is before the 114th Congress.
Access to Marketplace Insurance Act (H.R. 3742)
The Access to Marketplace Insurance Act was introduced on October 9, 2015, by Rep. Kevin Cramer (D-ND). The bill would prohibit insurance companies from discriminating against individuals with end-stage renal disease (ESRD) on dialysis by requiring that insurance companies accept payments directly from organizations like the American Kidney Fund. Currently, the Centers for Medicare and Medicaid Services (CMS) requires health insurance companies to accept payments directly from the Ryan White HIV/AIDS on behalf of patients with HIV/AIDS, but CMS does not require insurance companies to accept payments directly from other organizations on behalf of individuals with other medical conditions. Without a specific requirement from CMS, some insurance companies are now choosing to refuse the direct payments from these other organizations, which is discrimination against individuals with other medical conditions. The Access to Marketplace Insurance Act would require that insurance companies accept payments directly from organizations like the American Kidney Fund, which makes payments to health insurance companies on behalf of low-income and financially struggling dialysis patients. If enacted, the bill would stop the current discrimination.
The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (H.R. 1130, S. 598)
The American Kidney Fund strongly supports the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (H.R. 1130, S. 598). Introduced in February 2015 by Representatives Tom Marino (R-PA), John Lewis (D-GA) and Peter Roskam (R-IL) in the House and Senators Ben Cardin (D-MD), Mike Crapo (R-ID) and Bill Nelson (D-FL) in the Senate, this legislation would improve the coordination of patient care through a variety of measures, including allowing individuals under 65 with kidney failure to enroll in Medicare Advantage plans. It would also expand patient access to kidney disease education programs and home dialysis treatment options. The legislation would address kidney disease research, setting the nation on the path toward a cure through efficiently managed and coordinated biomedical research. The legislation would require the GAO to assess the adequacy of federal funding for CKD research relative to the expenditures for CKD care and identify gaps in research. The legislation also mandates a federal study to better understand the progression of kidney disease and treatment of kidney failure in minority populations.